Influenza Vaccination Strategy for Patients With Hematologic Malignancy

Recruiting now · Phase 3

Conditions studied: Hematologic Neoplasms, Influenza, Immunogenicity

In brief

This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population

Key facts

Study ID

NCT07485855

Run by

Asan Medical Center

People needed

60

Starts

2025-12-04

Expected to finish

2028-04-30

Last updated by the study team

2026-07-28

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 19 years or older
• Confirmed diagnosis of hematologic malignancy, including:
• non-Hodgkin lymphoma, Hodgkin lymphoma, acute leukemia, chronic leukemia, or plasma cell disorders

You may not qualify if…

• Difficulty with repeated venipuncture or blood sampling (e.g., poor vascular access or bleeding tendency)
• Cognitive or psychiatric impairment precluding understanding of or cooperation with study procedures
• Known hypersensitivity to influenza vaccine components
• Influenza vaccination within the preceding 6 months
• Any other condition deemed clinically inappropriate for study participation at investigator discretion

Where it is running

• Asan Medical Center — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.